Anti-VEGFs are currently suggested as the primary treatment for exudative AMD [2], and 5 anti-VEGF agents (ie, ranibizumab, aflibercept, brolucizumab, bevacizumab, and faricimab) are clinically accessible. Here, VEGFA is linked to age-related macular degeneration.